FDA clears XiO spot scanning software

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

The FDA has granted Elekta 510(k) clearance for its XiO spot scanning proton therapy planning software, which enables intensity modulated proton therapy.

Elekta, which develops devices and planning systems for treating cancer and brain disorders, said its XiO software facilitates rapid positioning of spots to construct the dose to the tumor. Spot scanning is a proton therapy delivery method that uses thousands of small individual beamlets, instead of one larger beam, to conform the dose to the tumor.

Stockholm-based Elekta indicated that XiO also includes a dose calculation algorithm to optimize each beam.